Latest Ratios: P/E Ratio -5.8x · EV/EBITDA N/A · ROE -49.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $2.6B | $1.3B | $975M | $937M | $236M | $59M | $15M | $90M | $201M | $54M |
| Enterprise Value | $1.6B | $2.5B | $1.2B | $893M | $787M | $194M | $13M | $-1500523 | $67M | $163M | $52M |
| P/E Ratio → | -5.84 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 24.64 | 37.25 | 4309.19 | 3104.38 | 528.93 | 79.53 | 55.73 | 3.37 | 10.70 | 50.14 | 16.25 |
| P/B Ratio | 2.28 | 3.65 | 1.94 | 2.21 | 2.37 | 1.26 | 0.49 | 0.95 | 1.75 | 5.21 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.97 | 4049.26 | 2843.93 | 444.10 | 65.60 | 12.45 | -0.34 | 8.03 | 40.77 | 15.56 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2595.6% | 100.0% | -262.8% | -390.2% | 23.6% |
| Operating Margin | -512.9% | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% | -10512.4% | -941.0% | -394.5% | -662.8% | -374.8% |
| Net Profit Margin | -483.6% | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -379.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.2% | -49.2% | -48.5% | -56.8% | -44.6% | -51.6% | -163.1% | -124.8% | -72.8% | -138.9% | -251.4% |
| ROA | -41.7% | -41.7% | -43.8% | -51.4% | -40.7% | -47.4% | -137.1% | -86.9% | -55.1% | -93.5% | -147.7% |
| ROIC | -47.3% | -47.3% | -47.0% | -63.1% | -51.5% | -54.1% | -224.3% | -222.9% | -165.3% | -2008.0% | — |
| ROCE | -47.7% | -47.7% | -51.6% | -58.8% | -45.4% | -51.3% | -156.9% | -105.6% | -61.3% | -110.0% | -247.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.03 | 0.05 | 0.01 | 0.01 | 0.00 | 0.53 | 0.20 | 0.26 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.12 | -0.19 | -0.38 | -0.22 | -0.38 | -1.05 | -0.43 | -0.97 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -68.24 | -68.24 | -87.62 | -127.71 | -266.23 | -26470.00 | -79.76 | -49.15 | -36.46 | -68.22 | -132.41 |
Net cash position: cash ($212M) exceeds total debt ($51M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.73 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.93 |
| Quick Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.93 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.91 |
| Cash Ratio | 12.37 | 12.37 | 14.99 | 17.92 | 12.73 | 14.44 | 11.96 | 2.64 | 9.28 | 12.17 | 0.73 |
| Asset Turnover | — | 0.08 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.15 | 0.13 | 0.08 | 0.78 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 39.81 |
| Days Sales Outstanding | — | — | — | 118.57 | 21.01 | 55.56 | — | 8.84 | 1.04 | 132.76 | 57.31 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $85M | $68M | $45M | $32M | $12M | $4M | $2M | $2M | $1M | $721410 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VRDN stock.
Viridian Therapeutics, Inc.'s current P/E ratio is -5.8x. This places it at the 50th percentile of its historical range.
Viridian Therapeutics, Inc.'s return on equity (ROE) is -49.2%. The historical average is -111.0%.
Based on historical data, Viridian Therapeutics, Inc. is trading at a P/E of -5.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Viridian Therapeutics, Inc. has 100.0% gross margin and -512.9% operating margin.
Key Metrics
Top Statement Risk
Clinical trial execution failure
Metrics are mathematically derived from official filings.
Speculative Valuation Reflects Pipeline Potential
Based on reported figures, the company trades at a price-to-sales multiple of 21.44, a valuation that appears to be driven entirely by market expectations of future clinical success rather than any underlying fundamental earnings power or established commercial revenue streams currently present in the financial statements.
The elevated P/S ratio suggests that investors are pricing the firm as a high-growth biotech entity, effectively discounting the significant execution risk inherent in the IGF-1R pipeline. This valuation level warrants caution, as it implies a high probability of successful commercialization that may not be supported by the current, non-recurring nature of the firm's milestone-based revenue.
Capital Compounding Remains Deeply Negative
According to recent SEC filings, the company's ROIC has remained consistently negative, reaching -16.3% in 2026Q1, which underscores the firm's current status as a capital-consuming R&D engine that has yet to demonstrate the ability to generate positive returns on its invested capital base.
The persistent decay in ROIC is a direct consequence of the heavy investment in Phase 3 clinical trials without offsetting product revenue. Investors should monitor whether the firm can pivot toward positive returns once the clinical development phase concludes, though current trends suggest that capital efficiency remains secondary to trial completion.
Working Capital Efficiency Remains Obscured
As reported in financial statements, the company's asset turnover ratio of 0.00 in recent periods highlights the lack of commercial operations, as the firm's balance sheet is dominated by cash and R&D-related assets rather than revenue-generating inventory or accounts receivable typical of an industrial business.
The absence of meaningful asset turnover indicates that the firm is not yet utilizing its capital to drive operational output. The erratic nature of the cash conversion cycle, when data is available, suggests that working capital management is currently a function of project-based milestone timing rather than sustainable operational efficiency.
Liquidity Buffer Supports Clinical Runway
Based on the provided data, the company maintains a current ratio of 15.15 as of 2026Q1, which appears to provide a sufficient liquidity cushion to fund ongoing clinical trials, though this metric is heavily inflated by the firm's reliance on cash reserves rather than operational cash flow.
While the high current ratio suggests a lack of immediate solvency risk, it masks the reality that the firm is burning through its cash reserves at an accelerating rate. The liquidity position should be viewed as a finite runway that necessitates future capital raises to sustain operations beyond the current clinical development cycle.
Misapplied Metrics Obscure Clinical Reality
The price-to-earnings ratio is the most commonly misapplied metric for this business model, as the firm's negative earnings of -5.39 TTM render traditional valuation multiples meaningless and fail to capture the binary nature of the company's clinical-stage assets and their associated development risks.
Investors should instead focus on cash burn rates and clinical trial milestones, as P/E ratios ignore the massive R&D expenditures that are essential for the firm's survival. Relying on earnings-based valuation in a pre-commercial biotech context risks misinterpreting the firm's true value, which is tied to the probability-weighted success of its pipeline.